Citations

Clear

4610 citation(s) found for "Lu, Brian".

Development and Pilot Testing of a Programmatic System for Competency Assessment in US Anesthesiology Residency Training
Woodworth, Glenn E. , Goldstein, Zachary, Arthur, Mary E. , Bailey, Caryl , Booth, Gregory J , Fromer, Ilana R. , Hallman, Matthew R., Hoang, Thomas, Isaak, Robert S. , Klesius, Lisa L. , Ladlie, Beth L., Mitchell, Sally A. , Juve, Amy K. Miller , McGrath, Brian J., Shepler, John A. , Sims, Charles R. , Spofford, Christina M., Tanaka, Pedro , Maniker, Robert B. , Ambardekar, Aditee P. , Carney, Patricia A. , Chen, Fei , Duncan, Michael J., Mitchell, John

Mayo Clinic

Anesthesia & Analgesia | October 6, 2023 | Volume: 138 | Issue: 5 | Pages: 1081-1093

10.1213/ane.0000000000006667 | PMID 37801598 Get It

BACKGROUND: In 2018, a set of entrustable professional activities (EPAs) and procedural skills assessments were developed for anesthesiology training, but they did not assess all the Accreditation Council for Graduate Medical Education (ACGME) milestones. The aims of this study were to (1) remap the 2018 EPA and procedural skills assessments to the revised ACGME Anesthesiology Milestones 2.0, (2) develop new assessments that combined with the original assessments to create a system of assessment that addresses all level 1 to 4 milestones, and (3) provide evidence for the validity of the assessments. METHODS: Using a modified Delphi process, a panel of anesthesiology education experts remapped the original assessments developed in 2018 to the Anesthesiology Milestones 2.0 and developed new assessments to create a system that assessed all level 1 through 4 milestones. Following a 24-month pilot at 7 institutions, the number of EPA and procedural skill assessments and mean scores were computed at the end of the academic year. Milestone achievement and subcompetency data for assessments from a single institution were compared to scores assigned by the institution’s clinical competency committee (CCC). RESULTS: New assessment development, 2 months of testing and feedback, and revisions resulted in 5 new EPAs, 11 nontechnical skills assessments (NTSAs), and 6 objective structured clinical examinations (OSCEs). Combined with the original 20 EPAs and procedural skills assessments, the new system of assessment addresses 99% of level 1 to 4 Anesthesiology Milestones 2.0. During the 24-month pilot, aggregate mean EPA and procedural skill scores significantly increased with year in training. System subcompetency scores correlated significantly with 15 of 23 (65.2%) corresponding CCC scores at a single institution, but 8 correlations (36.4%) were <30.0, illustrating poor correlation. CONCLUSIONS: A panel of experts developed a set of EPAs, procedural skill assessment, NTSAs, and OSCEs to form a programmatic system of assessment for anesthesiology residency training in the United States. The method used to develop and pilot test the assessments, the progression of assessment scores with time in training, and the correlation of assessment scores with CCC scoring of milestone achievement provide evidence for the validity of the assessments.
SAT455 A Randomized, Quadruple-masked, Placebo-controlled, Multicenter Trial To Evaluate The Efficacy And Safety Of Teprotumumab In Patients With Chronic (Inactive/Low CAS) Thyroid Eye Disease
Couch, Steven M., Wester, Sara T. , Fowler, Brian , Liu, Catherine , Tang, Rosa A. , Nguyen, Quang T., Karon, M , Douglas, Raymond S , Subramanian, Prem S. , Nguyen, Quang T, Hsu, Kate, Karon, Michael, Stan, Marius N.

Mayo Clinic

Journal of the Endocrine Society | October 5, 2023 | Volume: 7 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvad114.1930 Get It

Abstract Disclosure: R.S. Douglas: Consulting Fee; Self; Horizon Therapeutics plc, Immunovant, Viridian. S. Couch: None. S.T. Wester: Advisory Board Member; Self; Horizon Therapeutics plc. Consulting Fee; Self; Immunovant, Sling. B. Fowler: Consulting Fee; Self; Horizon Therapeutics plc. C. Liu: Other; Self; Walter Kluwer Health. P. Subramanian: Consulting Fee; Self; Gensight, Horizon Therapeutics plc, Viridian. R. Tang: Consulting Fee; Self; Viridian, Alexion, Valenza. Research Investigator; Self; Viridian, Horizon Therapeutics plc, Novartis, Immunovant, Vasaragen. Speaker; Self; Serono Speaker Journal Club. Q.T. Nguyen: None. K. Hsu: Employee; Self; Horizon Therapeutics plc. Stock Owner; Self; Horizon Therapeutics plc. M. Karon: Employee; Self; Horizon Therapeutics plc. Stock Owner; Self; Horizon Therapeutics plc. M.N. Stan: Consulting Fee; Self; Immunovant, Horizon Therapeutics plc, Sling, Genentech, ArgenX. Background: Thyroid eye disease (TED) is characterized by expansion of peri- and retro-orbital fat and muscle, often resulting in disfiguring proptosis (eye-bulging) and diplopia (double vision) which may persist chronically. Teprotumumab, an inhibitor of the insulin-like growth factor-1 receptor, demonstrated improvements in proptosis, diplopia, inflammation and quality of life in clinical trials in patients with TED history of short duration (6-13 months), and active disease (clinical activity score [CAS] ≥4). In a published study of 31 patients with CAS≤3 and TED duration &gt;2 years, teprotumumab reduced proptosis, diplopia and inflammation.1 We have undertaken the first randomized, placebo (PBO)-controlled trial to evaluate teprotumumab in patients with chronic/inactive/low CAS TED. The trial has completed randomization with results available in May 2023. Here we report characteristics of the randomized patients. Methods: The trial (NCT04583735) is being conducted in 11 centers in the United States. Key inclusion criteria were age≥18 years, TED duration ≥2 years but &lt;10 years and CAS≤1 in both eyes, ≥3mm proptosis from baseline and/normal for sex and race, or no progression in proptosis or diplopia or new inflammatory symptoms in the preceding year. Patients must have been euthyroid or mildly hypo/hyperthyroid, and not require surgical intervention through the trial. Patients could not have received teprotumumab previously, or steroids within 3 weeks before screening. Patients were randomized 2:1 to receive 8 infusions of teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for the remaining 7 infusions) or PBO once every 3 weeks. The primary endpoint is improvement in proptosis (mm) as compared with PBO from baseline at Week 24. Other endpoints include percentage of proptosis responders (improvement of ≥2mm), diplopia responders (improvement of ≥1 grade in diplopia on the Bahn-Gorman scale, 0-3), and improvement in Graves’ Ophthalmopathy- Quality of Life (GO-QoL), all at Week 24. Adverse events (AE) and AE of special interest will be reported. Results: 62 patients were randomized. 80.6% are female, mean (SD) age was 48.7 (14.94) years. 54.8% are White, 24.2 %, Black or African American, and 12.9%, Asian. Mean (SD) TED duration was 5.2 (1.77) years. 87.1% are never/former smokers. At baseline, mean (SD) proptosis in the study eye was 24.4 (2.94) mm, and mean (SD) CAS was 0.4 (0.49). 27.4% had binocular diplopia with a mean diplopia score of 2. The mean overall GO-QoL score was 63.9 indicating similar disutility as observed in the acute trial population (previously published). Results from this 24-week trial will be presented. Conclusions: Despite a long duration of TED and low “activity”, patients enrolled in this trial have high levels of proptosis and impaired quality of life at baseline. Presentation: Saturday, June 17, 2023
OR27-04 Efficacy And Safety Results From The Randomized, Placebo-controlled Multicenter Trial With Teprotumumab In Chronic-Low Clinical Activity Score Thyroid Eye Disease Patients
Couch, Steven M., Wester, Sara T. , Fowler, Brian , Liu, Catherine , Tang, Rosa A. , Nguyen, Quang T., Maamari, Robi N. , Karon, M , Douglas, Raymond S , Subramanian, Prem S. , Nguyen, Quang T, Hsu, Kate, Karon, Michael, Stan, Marius N.

Mayo Clinic

Journal of the Endocrine Society | October 5, 2023 | Volume: 7 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvad114.2055 Get It

Abstract Disclosure: R.S. Douglas: Consulting Fee; Self; Horizon, Immunovant, Viridian. Research Investigator; Self; Horizon. S. Couch: Research Investigator; Self; Horizon. S.T. Wester: Advisory Board Member; Self; Horizon. Consulting Fee; Self; Immunovant, Sling. Research Investigator; Self; Horizon. B.T. Fowler: Consulting Fee; Self; Horizon. Research Investigator; Self; Horizon. C. Liu: Research Investigator; Self; Horizon. Other; Self; Royalties from Wolters-Kluwer. P. Subramanian: Consulting Fee; Self; Horizon, Gensight, Viridian. Research Investigator; Self; Horizon. R. Tang: Consulting Fee; Self; Viridian, Alexion, Valenza. Research Investigator; Self; Horizon, Viridian, Novartis, Immunovant, Vasaragen. Speaker; Self; Serono Journal Club. Q.T. Nguyen: Research Investigator; Self; Horizon. R.N. Maamari: Research Investigator; Self; Horizon. K. Hsu: Employee; Self; Horizon. Stock Owner; Self; Horizon. M. Karon: Employee; Self; Horizon. Stock Owner; Self; Horizon. M. Stan: Consulting Fee; Self; Septerna Inc, Third Rock Ventures LLC, Genentech, MedicXi Ventures, ArgenX US Inc, Tourmaline Bio, Lassen Therapeutics, Ortho Clinical Diagnostics, Siemens Healthcare, Tolmar Inc, OSE, Immunotherapeutics, Roivant Sciences. Research Investigator; Self; Horizon, Immunovant, ValenzaBio, Sling Therapeutics. Background: Early inflammatory thyroid eye disease (TED) gives way to chronic disease which may lead to long-term disfiguring proptosis (eye-bulging). Teprotumumab, an IGF-1 receptor inhibitor, significantly improved signs and symptoms of newly diagnosed TED (6-13 months) with active disease (clinical activity score [CAS] ≥4) in prior studies. We present data from the first randomized, placebo (PBO)-controlled trial (NCT04583735) with teprotumumab in chronic/low CAS TED, where disease has not regressed. Methods: Pts met all following criteria: ≥18 yrs, TED 2-10 yrs, inactive disease or &gt;1 yr without progression in proptosis/diplopia/new symptoms, baseline (BL) CAS≤1, increased proptosis ≥3mm before TED or from normal, euthyroid/mildly hypo/hyperthyroid, no prior teprotumumab and no steroids within 3 wks of screen. Pts received teprotumumab or PBO once every 3 wks for 21 wks. Primary endpoint was improvement in proptosis(mm) from BL at Wk 24 vs PBO. Secondarily proptosis responders (≥2mm improvement), diplopia responders (≥1 grade improvement on Gorman scale 0-3) with resolved diplopia (grade 0) and improvement in Graves’ Ophthalmopathy-QoL (GO-QoL) visual function (VF) and appearance (AP) subscales were assessed. Treatment-emergent adverse events (TEAE) and AEs of special interest are reported. Study was solely sized/powered for proptosis. Results: 62 pts were randomized 2:1 (ITT, teprotumumab:42; PBO:20), 80.6% were female, mean(SD) age was 48.7(14.94) yrs. Mean(SD) TED duration was 5.2(1.8) yrs. 87.1% were never/former smokers. At BL, mean(SD) proptosis was 24.4(2.94) mm, mean CAS was 0.4, and 29% (teprotumumab, n=14, PBO, n=4) had diplopia with a mean score ∼2. 93%(39) of teprotumumab pts completed the study. At Wk 24, proptosis improvements from BL were significantly greater in the teprotumumab group [2.41 (0.228) mm] vs PBO [0.92(0.323) mm], P&lt;.001. Proptosis response was observed in 26/42 (62%) of teprotumumab pts vs 5/20 (25%) of PBO, P=.01. Diplopia improvement was observed in 6/14 (43%) teprotumumab pts with resolved diplopia in 4(29%) vs 2/4(50%) in PBO and 1(25%) resolved. Significantly greater improvement from BL was observed on GO-QoL-VF for teprotumumab (8.73) vs PBO (2.41), P=.03. Change from BL on AP was 10.03 vs 7.19, P= .65. TEAEs proportions were similar: 33/41(80.5%) of teprotumumab, and 16/20(80%) of PBO pts. Hyperglycemia was reported in 6(15%) vs 2(10%) and hearing impairment in 9(22%) vs 2(10%), respectively. There were two AE discontinuations: teprotumumab (left ear conductive hearing loss with congenital anomaly) and PBO (infusion related). Conclusions: For the first time in pts with longstanding TED and low CAS/inflammation, a medical therapy, teprotumumab, produced significant improvement in proptosis as compared with PBO supporting its use regardless of TED duration or activity. The safety profile was comparable to that previously reported. Presentation: Saturday, June 17, 2023
Effect of Electronic Health Record Prompts on the Frequency of Blood Lead Tests
Kellund, Anna , Hentz, Roland, Cristiani, Valeria, Lynch, Brian , Kellund, Anna E , Hentz, Roland C, Lynch, Brian A

Mayo Clinic

Journal of Primary Care & Community Health | October 5, 2023 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/21501319231204438 | PMID 37795858 Get It

Introduction/Objectives: Elevated blood lead levels can cause impaired cognition and behavioral problems in children. Screening is important for identifying children with elevated blood lead levels, but many children who qualify for screening do not get tested. We aimed to see if the addition of prompts in the electronic health record (EHR) would lead to differences in blood lead tests ordered for children with government insurance. Methods: In May 2018, a prompt was added to our institutional EHR that reminded primary care practitioners to recommend lead testing for patients with government insurance. For this retrospective observational pre-post comparative study, we reviewed the rate of blood lead test orders and completed collection before and after the prompt was introduced. Results: The number of blood lead tests ordered did not increase after prompts were introduced in the EHR; rather, the lead screening rates at 12-month well-child visits decreased from 63.6% to 53.8% ( P = .008). The 24-month visit data did not change significantly for the number of lead tests ordered before and after the prompt was introduced in the EHR. The number of lead tests completed showed a significant decrease after the prompt was introduced for the 12-month visit ( P < .001) but no significant change for the 24-month visit ( P = .70). Conclusions: This study showed that the addition of prompts in the EHR was not associated with an increase in the number of blood lead level tests ordered. Further research is needed to determine factors that could affect lead screening rates.
The devil’s in the details: Exploring historically low board pass rates in Blood Banking/Transfusion Medicine
Adkins, Brian D. , Usmani, Amena , Jacobs, Jeremy W. , Booth, Garrett S. , Jacobs, Jeremy W , Booth, Garrett , Adkins, Brian David , Stephens, Laura D.

Mayo Clinic

American Journal of Clinical Pathology | October 4, 2023 | Volume: 161 | Issue: 2 | Pages: 108-110

10.1093/ajcp/aqad127 | PMID 37793032 Get It

Clonal Somatic Mutations in Chronic Lung Diseases Are Associated with Reduced Lung Function
Yun, Jeong H. , Khan, Mehnaz, Ghosh, Auyon , Hobbs, Brian D. , Hersh, Craig P. , Cool, Carlyne D. , Barwick, Lucas, Flaherty, Kevin R. , Criner, Gerard J. , Brown, Kevin K. , Silverman, Edwin K. , DeMeo, Dawn L. , Bick, Alexander G. , Hersh, Craig P , Wise, Robert , Cho, Michael H , Ghosh, Auyon J , Yun, Jeong H , Bick, Alexander G , Criner, Gerard , Hobbs, Brian D , Castaldi, Peter J. , Miller, Peter G. , Sciurba, Frank C. , Limper, Andrew H. , Wise, Robert A. , Martínez, Fernando J. , Cho, Michael H.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | October 3, 2023 | Volume: 208 | Issue: 11 | Pages: 1196-1205

10.1164/rccm.202303-0395oc | PMID 37788444 Get It

Abstract Rationale Constantly exposed to the external environment and mutagens such as tobacco smoke, human lungs have one of the highest somatic mutation rates among all human organs. However, the relationship of these mutations to lung disease and function is not known. Objectives To identify the prevalence and significance of clonal somatic mutations in chronic lung diseases. Methods We analyzed the clonal somatic mutations from 1,251 samples of normal and diseased noncancerous lung tissue RNA sequencing with paired whole-genome sequencing from the Lung Tissue Research Consortium. We examined the associations of somatic mutations with lung function, disease status, and computationally deconvoluted cell types in two of the most common diseases represented in our dataset, chronic obstructive pulmonary disease (COPD; 29%) and idiopathic pulmonary fibrosis (IPF; 13%). Measurements and Main Results Clonal somatic mutational burden was associated with reduced lung function in both COPD and IPF. We identified an increased prevalence of clonal somatic mutations in individuals with IPF compared with normal control subjects and individuals with COPD independent of age and smoking status. IPF clonal somatic mutations were enriched in disease-related and airway epithelial–expressed genes such as MUC5B in IPF. Patients who were MUC5B risk variant carriers had increased odds of developing somatic mutations of MUC5B that were explained by increased expression of MUC5B. Conclusions Our identification of an increased prevalence of clonal somatic mutation in diseased lung that correlates with airway epithelial gene expression and disease severity highlights for the first time the role of somatic mutational processes in lung disease genetics.
Machine Learning for Automated Classification of Abnormal Lung Sounds Obtained from Public Databases: A Systematic Review
García-Méndez, Juan , Lal, Amos , Tekin, Aysun , Pinevich, Yuliya , Lipatov, Kirill , Qamar, Shahraz , Ayala, Ivan N. , Khapov, Ivan, Gerberi, Dana , Diedrich, Daniel A. , Pickering, Brian W. , Herasevich, Vitaly , Garcia-Mendez, Juan P, Herasevich, Svetlana , Tekin, Aysun , Wang, Hsin-Yi, Ayala, Iván Nicolas , Gerberi, Danielle J , Diedrich, Daniel, Herasevich, Vitaly , Lal, Amos , Garcia-Mendez, Juan P., Lipatov, Kirill , Wang, Hsin‐Yi

Mayo Clinic

Bioengineering | October 2, 2023 | Volume: 10 | Issue: 10 | Pages: 1155

10.3390/bioengineering10101155 | PMID 37892885 Get It

Pulmonary auscultation is essential for detecting abnormal lung sounds during physical assessments, but its reliability depends on the operator. Machine learning (ML) models offer an alternative by automatically classifying lung sounds. ML models require substantial data, and public databases aim to address this limitation. This systematic review compares characteristics, diagnostic accuracy, concerns, and data sources of existing models in the literature. Papers published from five major databases between 1990 and 2022 were assessed. Quality assessment was accomplished with a modified QUADAS-2 tool. The review encompassed 62 studies utilizing ML models and public-access databases for lung sound classification. Artificial neural networks (ANN) and support vector machines (SVM) were frequently employed in the ML classifiers. The accuracy ranged from 49.43% to 100% for discriminating abnormal sound types and 69.40% to 99.62% for disease class classification. Seventeen public databases were identified, with the ICBHI 2017 database being the most used (66%). The majority of studies exhibited a high risk of bias and concerns related to patient selection and reference standards. Summarizing, ML models can effectively classify abnormal lung sounds using publicly available data sources. Nevertheless, inconsistent reporting and methodologies pose limitations to advancing the field, and therefore, public databases should adhere to standardized recording and labeling procedures.
Magnetic Resonance Imaging of Iron Metabolism with T2* Mapping Predicts an Enhanced Clinical Response to Pharmacologic Ascorbate in Patients with GBM
Petronek, Michael S. , Monga, Varun , Bodeker, Kellie L. , Kwofie, Michael , Lee, Chu‐Yu , Stolwijk, Jeffrey M. , Zaher, Amira , Wagner, Brett A. , Smith, Mark C. , Vollstedt, Sandy , Brown, Heather , Chandler, Meghan L. , Lorack, Amanda C. , Wulfekuhle, Jared S. , Flynn, Ryan T. , Jones, Karra A. , Magnotta, Vincent A. , Mapuskar, Kranti A , Stolwijk, Jeffrey M , Zaher, Amira , Wagner, Brett A , Smith, Mark C , Vollstedt, Sandy , Brown, Heather , Chandler, Meghan L , Lorack, Amanda C , Wulfekuhle, Jared S , Sarkaria, Jann N , Flynn, Ryan T , Greenlee, Jeremy D W , Howard, Matthew A , Smith, Brian J , Jones, Karra A , Buettner, Garry R , Cullen, Joseph J , St-Aubin, Joel , Buatti, John M , Magnotta, Vincent A , Spitz, Douglas R , Allen, Bryan G , Monga, Varun , Mapuskar, Kranti A. , Sarkaria, Jann N. , Greenlee, Jeremy D.W. , Howard, Matthew A. , Buettner, Garry R. , Buatti, John M. , Spitz, Douglas R.

Mayo Clinic

Clinical Cancer Research | September 29, 2023 | Volume: 30 | Issue: 2 | Pages: 283-293

10.1158/1078-0432.ccr-22-3952 | PMID 37773633 Get It

Abstract Purpose: Pharmacologic ascorbate (P-AscH−) is hypothesized to be an iron (Fe)-dependent tumor-specific adjuvant to chemoradiation in treating glioblastoma (GBM). This study determined the efficacy of combining P-AscH− with radiation and temozolomide in a phase II clinical trial while simultaneously investigating a mechanism-based, noninvasive biomarker in T2* mapping to predict GBM response to P-AscH− in humans. Patients and Methods: The single-arm phase II clinical trial (NCT02344355) enrolled 55 subjects, with analysis performed 12 months following the completion of treatment. Overall survival (OS) and progression-free survival (PFS) were estimated with the Kaplan–Meier method and compared across patient subgroups with log-rank tests. Forty-nine of 55 subjects were evaluated using T2*-based MRI to assess its utility as an Fe-dependent biomarker. Results: Median OS was estimated to be 19.6 months [90% confidence interval (CI), 15.7–26.5 months], a statistically significant increase compared with historic control patients (14.6 months). Subjects with initial T2* relaxation &lt; 50 ms were associated with a significant increase in PFS compared with T2*-high subjects (11.2 months vs. 5.7 months, P &lt; 0.05) and a trend toward increased OS (26.5 months vs. 17.5 months). These results were validated in preclinical in vitro and in vivo model systems. Conclusions: P-AscH− combined with temozolomide and radiotherapy has the potential to significantly enhance GBM survival. T2*-based MRI assessment of tumor iron content is a prognostic biomarker for GBM clinical outcomes. See related commentary by Nabavizadeh and Bagley, p. 255
No Increased Mercury Release from Dental Restorations at 1.5T, 3T, or 7T MRI
Burkett, Brian J. , Rasmussen, Chad M. , Fillmore, W. Jonathan , McDonald, Robert J. , Fagan, Andrew , Erdahl, Sarah A , Eckdahl, Steven J., Welker, Kirk M. , Fagan, Andrew J , Burkett, Brian , McDonald, Jennifer S.

Mayo Clinic

Magnetic Resonance in Medicine | September 27, 2023 | Volume: 91 | Issue: 2 | Pages: 660-669

10.1002/mrm.29872 | PMID 37755142 Get It

AbstractPurposeDental amalgam contains mercury and is commonly used in dental restorations. The impact of MRI on mercury excretion from dental amalgam is not well understood across clinical field strengths, especially 7T. We investigated the effects of MRI exposure on mercury excretion using fresh, lab‐created dental amalgam restorations and in extracted teeth with old, pre‐existing restorations.MethodsDonated, unfilled human teeth (n = 120) were restored with amalgam before being stored in saline, artificial saliva, or a dry box prior to MRI scanning. The teeth were placed in individual tubes of fresh artificial saliva and scanned at 1.5T, 3T, or 7T or left unscanned as controls. Mercury concentrations were measured 24–30 h later. Donated teeth with pre‐existing restorations (n = 40) were stored in artificial saliva, scanned at 7T or left unscanned as controls, and mercury concentration tested.ResultsFor teeth extracted and restored in a laboratory, no significant difference was found (F = 2.42, P = 0.072) between mean mercury concentrations of unscanned teeth (13.72 μg/L) and teeth scanned at 1.5T (10.88 μg/L), 3T (12.65 μg/L), or 7T (8.88 μg/L). For teeth extracted with previously placed restorations, no significant difference (P = 0.288) was found between unscanned controls (4.28 μg/L) and teeth scanned at 7T (6.63 μg/L).ConclusionMRI of dental amalgam does not significantly increase mercury excretion at 1.5T, 3T, or 7T compared to unscanned teeth. This holds true for controlled laboratory restorations as well as for those placed and lived with prior to extraction and scanning, demonstrating no added risk to the clinical patient or research subject.
Birth prevalence and characteristics of congenital corneal opacities
Borik, Kaitlynn, Mohney, Brian G. , Hodge, David O. , Reynolds, Margaret , Hodge, David, Reynolds, Margaret M

Mayo Clinic

European Journal of Ophthalmology | September 25, 2023 | Volume: 34 | Issue: 3 | Pages: 734-738

10.1177/11206721231202900 | PMID 37743596 Get It

Purpose/Aim To report the birth prevalence and natural history of congenital corneal opacities among a population-based cohort of children. Materials and methods The medical records of patients <5 years diagnosed with a congenital onset corneal opacity while residing in Olmsted County, Minnesota, from January 1, 1977, through December 31, 2016, were retrospectively reviewed. Results Fourteen patients were diagnosed with a congenital corneal opacity during the 40-year study period for a birth prevalence of 1 in 5188 live births. The mean age at diagnosis was 7.5 months (range 0–48 months) and 9 (64.3%) were males. Four patients had congenital glaucoma, 4 had limbal dermoids, 2 had sclerocornea, and 1 patient each had Descemet's tear from birth trauma, herpes simplex virus type 1 keratitis, corneal leukoma, and an undiagnosed scar. Six (42.8%) patients required treatment for their underlying corneal opacity including the four patients with congenital glaucoma. The other 8 (57.1%) patients had a clear central axis. Four (28.6%) of 14 patients required amblyopia therapy, and 4 (28.6%) developed strabismus. Four (28.6%) patients had associated systemic conditions. During a mean follow up of 5.4 years (range 1.3–27.0 years), the median best corrected visual acuity (BCVA) was logmar 0.16 (20/25) (range 20/20-hand motion) with one patient with unilateral BCVA less than 20/60 and one patient with bilateral BCVA less than 20/60. Conclusions In this 40-year cohort, congenital corneal opacities were relatively rare and the result of a variety of disorders. Although amblyopia and strabismus occurred commonly, most patients had good visual outcomes.